跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Salubrinal
首页
药物
Salubrinal
Salubrinal
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
TREATMENT AND PREVENTION OF PULMONARY INJURY
申请人: UAB RES FOUND
优先权: 2019
US
WO
3 件公开
Cell Culture Media Supplement and Method of Molecular Stress Control
申请人: BAUST JOHN M
优先权: 2011
US
3 件公开
Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions
申请人: ALS THERAPY DEVELOPMENT INST
优先权: 2019
US
2 件公开
Method of Treating Cancer with a Combination of a Proteasome Inhibitor and Salubrinal
申请人: SCHEWE DENIS M
优先权: 2009
US
Compound medicinal composition for treating acute lymphocytic leukemia
申请人: UNIV CHINA PHARMA
优先权: 2010
CN
MIXED AMINAL PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
申请人: FRID MICHAEL
优先权: 2011
US
SALUBRINAL-DRIVEN ATTENUATION OF MALIGNANT PHENOTYPES OF 4T1 BREAST CANCER CELLS
申请人: UNIV INDIANA RES & TECH CORP
优先权: 2014
US
种用于严重烧伤治疗的免疫调节剂
申请人: 中国人民解放军总医院第附属医院
优先权: 2014
CN
Applications of small molecular compound Salubrinal in drugs for treating or preventing osteoporosis and osteopenia diseases
申请人: ZHANG PING
优先权: 2020
CN
New application of Salubrinal in preparation of medicine for treating aging of bone marrow mesenchymal stem cells
申请人: JIANGSAN UNIV
优先权: 2022
CN
第 1 / 2 页
上一页
下一页
药物
反馈